SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Antex Biologics (ANTX)
ANTX 1.100-3.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John R Resseger who wrote (1182)2/10/1999 9:29:00 AM
From: gammaray  Read Replies (1) of 1476
 
news of interest

Smith kline beecham is selling off a couple divisions in order to concntrate on more profitable research development. As everyone here knows, I would hope, sbh is a major source of funds for antx. Exerpt from news article as follows:

<<<Seeking to refocus on its core drug business and raise cash to increase research spending, SmithKline agreed to sell Diversified
Pharmaceutical Services to Express Scripts for $700 million. That's just a third of what SmithKline paid to acquire Diversified
in 1994.>>

Neil
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News